Endocrinol Metab.  2022 Jun;37(3):430-431. 10.3803/EnM.2022.303.

Sclerostin as a Putative Myokine in Sarcopenia

• Yi HS

• KMID: 2531386
• DOI: http://doi.org/10.3803/EnM.2022.303

Reference

1. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013; 19:179–92.

2. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23:860–9.

3. Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011; 26:373–9.

4. Saeki C, Tsubota A. Influencing factors and molecular pathogenesis of sarcopenia and osteosarcopenia in chronic liver disease. Life (Basel). 2021; 11:899.

5. Nga HT, Jang IY, Kim DA, Park SJ, Lee JY, Lee S, et al. Serum GDF15 level is independent of sarcopenia in older Asian adults. Gerontology. 2021; 67:525–31.

6. Larsson L, Degens H, Li M, Salviati L, Lee YI, Thompson W, et al. Sarcopenia: aging-related loss of muscle mass and function. Physiol Rev. 2019; 99:427–511.

7. Dao T, Green AE, Kim YA, Bae SJ, Ha KT, Gariani K, et al. Sarcopenia and muscle aging: a brief overview. Endocrinol Metab (Seoul). 2020; 35:716–32.

8. Tian J, Chung HK, Moon JS, Nga HT, Lee HY, Kim JT, et al. Skeletal muscle mitoribosomal defects are linked to low bone mass caused by bone marrow inflammation in male mice. J Cachexia Sarcopenia Muscle. 2022; 13:1785–99.

9. Ahn SH, Jung HW, Lee E, Baek JY, Jang IY, Park SJ, et al. Decreased serum level of sclerostin in older adults with sarcopenia. Endocrinol Metab (Seoul). 2022; 37:487–96.

10. Kim JA, Roh E, Hong SH, Lee YB, Kim NH, Yoo HJ, et al. Association of serum sclerostin levels with low skeletal muscle mass: the Korean Sarcopenic Obesity Study (KSOS). Bone. 2019; 128:115053.

11. Rooyackers OE, Nair KS. Hormonal regulation of human muscle protein metabolism. Annu Rev Nutr. 1997; 17:457–85.

12. Setoyama D, Lee HY, Moon JS, Tian J, Kang YE, Lee JH, et al. Immunometabolic signatures predict recovery from thyrotoxic myopathy in patients with Graves’ disease. J Cachexia Sarcopenia Muscle. 2022; 13:355–67.